More work needed for EU RMP initiative to be fully beneficial, says generics industry
This article was originally published in SRA
The EU generics industry says that while a new initiative that aims to help drug makers in the EU, especially generics companies, prepare risk management plans is a step in the "right direction", "further steps" are needed to ensure that the initiative is fully beneficial for the sector1-3.
You may also be interested in...
From looking at ways to reduce the number of audits undertaken by companies to fulfil their pharmacovigilance obligations to calling for harmonized assessment of risk management plans, the EU generics and biosimilars industry group Medicines for Europe says it is ready to explore some radical proposals to simplify the current pharmacovigilance requirements.
Stay current on regulatory guidelines from around the world with Medtech Insight's Guidance Tracker. Thirty-eight guidance documents have been posted on the tracker since its last update.
New treatments for advanced endometrial cancer and hereditary angioedema are among six drugs that have just been recommended for EU-wide approval. Harmonized EU advice has also been issued in relation to an investigational antibody combination for treating COVID-19.